| Business Summary | | Neoprobe
Corporation
is
a
developer
of
gamma-guided
surgery
dedicated
to
improving
the
diagnosis,
treatment
and
quality-of-life
of
cancer
patients.
The
Company
is
focused
on
its
two
primary
technologies,
Gamma
Detection
Systems
for
Lymphatic
Mapping
and
other
applications
and
the
RIGS
(radioimmunoguided
surgery)
Technology.
The
Company's
patented
gamma
detection
systems
consist
of
handheld
detector
probes
and
a
control
unit.
The
detection
device
in
the
tip
of
the
probe
is
a
highly
radiosensitive
crystal
that
relays
a
signal
through
a
preamplifier
to
the
control
unit
to
produce
both
a
digital
readout
and
an
audible
signal.
The
RIGS
system
is
an
investigational
technology
that
combines
a
patented
handheld
gamma
radiation
detection
probe,
proprietary
disease-specific
radio-labeled
cancer-targeting
agents
and
a
patented
surgical
method
to
provide
surgeons
with
real-time
information
to
locate
tumor
deposits
and
assist
in
more
thorough
removal
of
the
cancer. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | NEOP
is
a
development
stage
enterprise
engaged
in
the
development
and
commercialization
of
technologies
for
the
diagnosis
and
treatment
of
cancers.
For
the
three
months
ended
3/31/01,
net
sales
decreased
13%
to
$1.6
million.
Net
income
applicable
to
Common
totaled
$81
thousand
vs.
a
loss
of
$792
thousand.
Revenues
reflect
a
decrease
in
instrument
sales.
Net
income
reflects
the
absence
of
a
$765
thousand
loss
on
the
retirement
of
preferred
stock. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
2,277;
after
tax
earnings
were
177. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Julius Krevans, M.D., 76 Chairman | -- | David Bupp, 51 Pres,
CEO | $553K | Brent Larson, 37 CFO,
VP-Fin., Treasurer, Assistant Sec. | 229K | Carl Bosch, 44 VP,
Instrument Devel. | 233K | Rodger Brown, 50 VP,
Regulatory Affairs and Quality Assurance | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|